Evidence map›Paper›PMID 39438992›Full record

ArticleJournal of eating disorders2024

Psychedelics and the treatment of eating disorders: considerations for future research and practice.

Emilie Lacroix, Karsten Fatur, Phillipa Hay, Stephen Touyz, Aaron Keshen

Abstract readLetter
In one paragraph

Article in Journal of eating disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emilie LacroixDepartment of Psychology, University of New Brunswick, 38 Dineen Drive, Fredericton, NB, Canada. elacroix@unb.ca.
Karsten FaturDepartment of Psychology, University of New Brunswick, 38 Dineen Drive, Fredericton, NB, Canada.
Phillipa HayTranslational Health Research Institute, School of Medicine, Western Sydney University, Campbelltown, Australia.
Stephen TouyzInside Out Institute, University of Sydney, and Sydney Local Health District, Sydney, NSW, Australia.
Aaron KeshenDepartment of Psychiatry, Dalhousie University, 5909 Veterans Memorial Lane, Halifax, NS, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent trials have shown promising results for the use of psychedelic-assisted therapies in treating severe refractory psychiatric illnesses, and there has been growing interest in examining the effectiveness of these therapies in treating eating disorders. To move forward in a safe, ethically sound, and scientifically rigorous manner, the field must address critical considerations. In this Comment article, we outline important risks and ethical considerations, along with methodological aspects that require careful consideration in the design of psychedelic-assisted therapy trials. We conclude by providing provisional guidelines for clinical research trials to help shape the future of this work, with the aim of investigating and employing the use of psychedelics for treating eating disorders in a manner that protects clients and research participants while maximizing methodological rigour.

Indexed as

Eating disordersEthicsMethodologyPsychedelicsTreatment

Identifiers

PMID39438992
PMCPMC11495088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.